BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development
Portfolio Pulse from Benzinga Newsdesk
BioMed X Institute has started its first research project in collaboration with Sanofi. The project aims to develop a computational platform that can predict the efficacy of drug candidates in virtual patient populations with high accuracy. This could address the pharmaceutical industry's current 90% failure rate of new drug candidates during clinical development.
June 29, 2023 | 9:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sanofi's collaboration with BioMed X on a project to develop a computational platform for predicting drug efficacy could potentially reduce the high failure rate of new drug candidates, which could positively impact Sanofi's drug development process and future revenues.
The collaboration with BioMed X could potentially lead to a significant improvement in Sanofi's drug development process by reducing the failure rate of new drug candidates. This could lead to more successful drugs being brought to market, potentially increasing Sanofi's future revenues and positively impacting its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100